Tracy I. George, MD, discusses how ultra-sensitive duplex sequencing expands diagnostic capabilities in ISM by improving the detection of KIT mutations.
Nitin Jain, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the potential of combining atezolizumab, a humanized monoclonal anti–PD-L1 antibody,…
Endometrial cancer (EC) is increasing significantly among women in low- and middle-income countries (LMICs). EC detection may be improved by WID-qEC testing, a DNA methylation-based…
Ultra-sensitive tissue-free ctDNA testing showed that baseline ctDNA was associated with larger pathological tumor size in HR-positive breast cancer.
Elacestrant increased real-world TTNT for patients with ESR1-mutant HR-positive/HER2-negative breast cancer vs PFS from the phase 3 EMERALD trial.
Fixed-duration acalabrutinib combination improves PFS in CLL, imlunestrant ± abemaciclib boosts PFS in ESR1-mutated ER+ breast cancer, and more.
Tracy I. George, MD, discusses how ultra-sensitive duplex sequencing expands diagnostic capabilities in ISM by improving the detection of KIT mutations.
Sacituzumab govitecan has received FDA breakthrough therapy designation for patients with extensive-stage small cell lung cancer in the second line.
Stacey A. Cohen, MD, provides an overview on the current landscape of immunotherapies and prognostic tools in the treatment of colorectal cancer.
The new Cancer AI Alliance includes Fred Hutch, Dana-Farber, Memorial Sloan Kettering, The Sidney Kimmel Comprehensive Cancer Center and the Whiting School of Engineering at…
